利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.047 秒)

    ECDN protein and DNA encoding the same
    1.
    发明授权
    ECDN protein and DNA encoding the same 失效
    ECDN蛋白和编码相同的DNA

    公开(公告)号：US5871916A

    公开(公告)日：1999-02-16

    申请号：US649619

    申请日：1996-05-02

    申请人： Yusuke Nakamura ,  Hiroko Saito

    发明人： Yusuke Nakamura ,  Hiroko Saito

    IPC分类号： A61K38/00 ,  C07K14/72 ,  C12N15/12 ,  C12Q1/68 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C07K14/721 ,  C07K14/72 ,  A61K38/00

    摘要： A DNA encoding a novel steroid hormone receptor-like protein was obtained from a human fetal lung cDNA library, and its structure was determined. Further, the protein encoded by the gene was isolated, identified, and designated as an ECDN protein. Furthermore, a protein encoded by a DNA lacking a part of the above gene was isolated, identified, and designated as an ECDN paucimolecular protein.It was proven that the ECDN paucimolecular protein was expressed in various cancer cells. Therefore, it is expected that it becomes possible to diagnose and treat cancers by analyzing the expression of the ECDN protein and the ECDN paucimolecular protein in a subject tissue. Furthermore, attained to develop novel pharmaceuticals can be developed by finding natural and synthetic compounds capable of binding specifically to the ECDN protein and the ECDN paucimolecular protein.

    摘要翻译： PCT No.PCT / JP95 / 01909 Sec。 371日期：1996年5月2日 102（e）日期1996年5月2日PCT提交1995年9月21日PCT公布。 公开号WO96 / 09324 日期1996年3月28日从人胎儿肺cDNA文库获得编码新型类固醇激素受体样蛋白的DNA，测定其结构。 此外，由该基因编码的蛋白质被分离，鉴定并命名为ECDN蛋白。 此外，由缺乏上述基因的一部分的DNA编码的蛋白质被分离，鉴定并命名为ECDN分子蛋白。 证明ECDN微囊分子蛋白在各种癌细胞中表达。 因此，通过分析对象组织中的ECDN蛋白质和ECDN微分子蛋白质的表达，可以预测癌症的诊断和治疗。 此外，通过发现能够特异性结合ECDN蛋白质和ECDN微分子蛋白质的天然和合成化合物，可以开发开发新型药物。

    SEMA5B peptides and vaccines including the same
    2.
    发明授权
    SEMA5B peptides and vaccines including the same 有权
    SEMA5B肽和疫苗包括它们

    公开(公告)号：US09187556B2

    公开(公告)日：2015-11-17

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K14/00 ,  C07K16/18 ,  C07K14/47 ,  G01N33/574 ,  A61K39/00 ,  A61K38/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

    ECT2 peptides and vaccines including the same
    5.
    发明授权
    ECT2 peptides and vaccines including the same 有权
    ECT2肽和疫苗包括它们

    公开(公告)号：US08951975B2

    公开(公告)日：2015-02-10

    申请号：US13638272

    申请日：2011-03-30

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K38/08 ,  A61K38/10 ,  A61K38/00 ,  A61K38/04 ,  C07K7/06 ,  A61K39/00

    CPC分类号： C07K7/06 ,  A61K39/0011 ,  A61K2039/572

    摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.

    摘要翻译： 衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性 的原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包​​括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌 ，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

    Method of diagnosing esophageal cancer
    7.
    发明授权
    Method of diagnosing esophageal cancer 有权
    诊断食管癌的方法

    公开(公告)号：US08771963B2

    公开(公告)日：2014-07-08

    申请号：US13246639

    申请日：2011-09-27

    申请人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    IPC分类号： C12Q1/00 ,  G01N1/00 ,  G01N33/53 ,  G01N33/566 ,  G01N33/567 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y10T436/25

    摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.

    摘要翻译： 为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子，构建了代表32,256个基因的cDNA微阵列，分析19例食管鳞状细胞癌（ESCCS）的表达谱 ）通过激光捕获显微切割纯化。 本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。 这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。 此外，本文公开了与淋巴结转移和手术后复发相关的基因。 在候选分子靶基因中，进一步表征ECT2，CDC45L和DKK1。 用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。 因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。

    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME
    8.
    发明申请
    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    SEMA5B肽和疫苗，包括它们

    公开(公告)号：US20140178409A1

    公开(公告)日：2014-06-26

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。